PharmaNet Canada, HMR sign agreement to investigate renel drugs
With this agreement, PharmaNet will have to access potential subjects who are suffering from mild, moderate, or severe impaired renal function. PharmaNet Early Stage Development president Riaz Bandali
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.